Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Steffens, Sandra ^a   Köhler, Astrid ^a   Rudolph, Raphael ^a   Eggers, Hendrik ^a   Seidel, Christoph ^a   Janssen, Martin ^b   Wegener, Gerd ^a   Schrader, Mark ^a   Kuczyk, Markus A ^a   Schrader, Andres J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Biomarker; C reactive protein; Prognosis; Renal cell cancer; Survival

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SURVIVAL RATE; VALIDATION STUDY;

ADOLESCENT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; GERMANY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865826931     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-399     Document Type: Article

References (30)

1. Ljungberg B. Prognostic factors in renal cell carcinoma. Der Urologe Ausg 2004, 43(Suppl 3):119-120.
2. Kozlowski JM. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am 1994, 21:601-624.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875. 10.1056/NEJM199609193351207, 8778606.
4. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994, 12:206-212.
5. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995, 154:28-31. 10.1016/S0022-5347(01)67215-X, 7776446.
6. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008, 113:450-460. 10.1002/cncr.23566, 2785036, 18523999.
7. George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007, 7:1737-1747. 10.1586/14737140.7.12.1737, 18062748.
8. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005, 173:52-55. 10.1097/01.ju.0000146713.50673.e5, 15592024.
9. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
10. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003, 88:348-353. 10.1038/sj.bjc.6600768, 2747541, 12569375.
11. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007, 61:824-833. 10.1136/jech.2006.051292, 2703800, 17699539.
12. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989, 250:607-610. 10.1016/0014-5793(89)80805-1, 2787758.
13. Koo AS, Armstrong C, Bochner B, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 1992, 35:91-105.
14. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009, 27:2217-2224. 10.1200/JCO.2008.19.8440, 19289618.
15. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006, 15:381-384. 10.1158/1055-9965.EPI-05-0626, 16492932.
16. Yoshida S, Saito K, Koga F, et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008, 101:978-981. 10.1111/j.1464-410X.2007.07408.x, 18190628.
17. Saito K, Kawakami S, Ohtsuka Y, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007, 100:269-273. 10.1111/j.1464-410X.2007.06934.x, 17488302.
18. McArdle PA, Mir K, Almushatat AS, et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006, 77:127-129. 10.1159/000093905, 16888416.
19. Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009, 181:1004-1012. discussion 1012, 10.1016/j.juro.2008.10.156, 19150550.
20. Kawata N, Nagane Y, Yamaguchi K, et al. How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol 2008, 15:299-303. 10.1111/j.1442-2042.2008.01990.x, 18380815.
21. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007, 99:77-80. 10.1111/j.1464-410X.2006.06497.x, 16956357.
22. Ito K, Asano T, Yoshii H, et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006, 13:1365-1370. 10.1111/j.1442-2042.2006.01563.x, 17083384.
23. Jabs WJ, Busse M, Kruger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005, 68:2103-2110. 10.1111/j.1523-1755.2005.00666.x, 16221209.
24. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007, 110:1241-1247. 10.1002/cncr.22896, 17639589.
25. Lamb GW, McArdle PA, Ramsey S, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008, 102:756-761. 10.1111/j.1464-410X.2008.07666.x, 18384626.
26. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008, 101:959-963. 10.1111/j.1464-410X.2007.07363.x, 18190639.
27. Johnson THW, Abbasi A, Michigan A, Ogan K, Pattaras J, Kucuk O, Nieh P, Marshall F, Master V. CRP- based classification of localized renal cell carcinoma into low, intermediate and high riskof mortality. J Urol 2011, 185(4S):e667. abstract 1660.
28. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 2004, 91:1236-1238. 10.1038/sj.bjc.6602152, 2409897, 15354220.
29. Masuda H, Kurita Y, Fukuta K, et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998, 5:418-422. 10.1111/j.1442-2042.1998.tb00380.x, 9781427.
30. Johnson TMV, Abbasi A, Kucuk O, Young A, Ogan K, Patteras J, Nieh P, Marshall F, Osunkoya A. Intratumoral C-reative proein as a biomarker of pronosis in localized ranl cell carcinoma. J Urol 2011, 185(4S):e667. abstract #1661.